Cost containment analysis of childhood vaccination against varicella in Israel (Q35628187)

9 August 2017

1 reference

title

Cost containment analysis of childhood vaccination against varicella in Israel (English)

1 reference

9 August 2017

0 references

Ginsberg GM

1

1 reference

PubMed ID

14720487

9 August 2017

Somekh E

series ordinal

2

1 reference

9 August 2017

1 February 2004

1 reference

9 August 2017

1 reference

9 August 2017

48

1 reference

9 August 2017

119-133

1 reference

9 August 2017

2

1 reference

Community impact of childhood varicella infections

9 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900079-3

7 January 2021

The epidemiology of varicella and its complications.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900079-3

7 January 2021

Cost of chickenpox in Canada: part I. Cost of uncomplicated cases.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900079-3

7 January 2021

Management of chickenpox in the adult. A review prepared for the UK Advisory Group on Chickenpox on behalf of the British Society for the Study of Infection

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900079-3

7 January 2021

Varicella-zoster virus epidemiology--a changing scene?

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900079-3

7 January 2021

Consequences of varicella and herpes zoster in pregnancy: prospective study of 1739 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900079-3

7 January 2021

Outcome after maternal varicella infection in the first 20 weeks of pregnancy.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900079-3

7 January 2021

Congenital varicella in term infants: risk reconsidered

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900079-3

7 January 2021

Bacterial complications of primary varicella in children

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900079-3

7 January 2021

THE EPIDEMIOLOGY OF VARICELLA-ZOSTER VIRUS INFECTIONS

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900079-3

7 January 2021

A long-term prospective study of varicella vaccine in healthy children

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900079-3

7 January 2021

Efficacy of high-titer live attenuated varicella vaccine in healthy young children

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900079-3

7 January 2021

Immunogenicity and safety of a live attenuated varicella vaccine (Oka/SB Bio) in healthy children

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900079-3

7 January 2021

Varicella vaccine: the Japanese experience

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900079-3

7 January 2021

Immunization of healthy adults with live attenuated varicella vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900079-3

7 January 2021

Efficacy, immunogenicity, safety, and use of live attenuated chickenpox vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900079-3

7 January 2021

Postlicensure effectiveness of varicella vaccine during an outbreak in a child care center

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900079-3

7 January 2021

The effectiveness of the varicella vaccine in clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900079-3

7 January 2021

Live attenuated varicella virus vaccine. Efficacy trial in healthy children

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900079-3

7 January 2021

Varicella vaccine trials in healthy children. A summary of comparative and follow-up studies

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900079-3

7 January 2021

Oka/Merck varicella vaccine in healthy children: final report of a 2-year efficacy study and 7-year follow-up studies

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900079-3

7 January 2021

An economic analysis of varicella vaccination for health care workers

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900079-3

7 January 2021

The cost-effectiveness of introducing a varicella vaccine to the New Zealand immunisation schedule.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900079-3

7 January 2021

Varicella vaccine--the first six years

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900079-3

7 January 2021

The cost-effectiveness of varicella vaccination in Canada

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900079-3

7 January 2021

The value of varicella vaccination in healthy children: cost-benefit analysis of the situation in France

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900079-3

7 January 2021

Postlicensure safety surveillance for varicella vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900079-3

7 January 2021

An economic evaluation of varicella vaccine for pediatric liver and kidney transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900079-3

7 January 2021

Childhood vaccination against chickenpox: an analysis of benefits and costs

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900079-3

7 January 2021

Theoretical epidemiologic and morbidity effects of routine varicella immunization of preschool children in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900079-3

7 January 2021

The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900079-3

7 January 2021

Cost effectiveness of vaccination strategies in adults without a history of chickenpox

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900079-3

7 January 2021

Cost-effectiveness of routine antenatal varicella screening.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900079-3

7 January 2021

The cost-effectiveness of varicella screening and vaccination in U.S. Army recruits

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900079-3

7 January 2021

Controlling varicella in the healthcare setting: the cost effectiveness of using varicella vaccine in healthcare workers

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900079-3

7 January 2021

Cellular immune response of a varicella vaccine following simultaneous DTaP and VZV vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900079-3

7 January 2021

Interference between strains in live virus vaccines. II: Combined vaccination with varicella and measles-mumps-rubella vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900079-3

7 January 2021

The burden of uncomplicated cases of chickenpox in Israel.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900079-3

7 January 2021

Epidemiology of chickenpox in England and Wales, 1967-85.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900079-3

7 January 2021

Social epidemiology of chickenpox in two British national cohorts

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900079-3

7 January 2021

Chickenpox hospitalizations among residents of Olmsted County, Minnesota, 1962 through 1981. A population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900079-3

7 January 2021

Hospitalization for primary varicella-zoster virus infection and its complications in patients from Southern Israel

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900079-3

7 January 2021

A cost-benefit analysis of legislation for bicycle safety helmets in Israel

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900079-3

7 January 2021

The cost of childhood chickenpox: parents' perspective.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900079-3

7 January 2021

Rapid enzyme-linked immunosorbent assay for detecting antibody to varicella-zoster virus

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900079-3

7 January 2021

Analysis of varicella vaccine breakthrough rates: implications for the effectiveness of immunisation programmes.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900079-3

7 January 2021

The cost-effectiveness of routine childhood varicella vaccination in Germany

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900079-3

7 January 2021

Direct and indirect costs of chickenpox in young children.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900079-3

7 January 2021

Cost of chickenpox in Canada: part II. Cost of complicated cases and total economic impact. The Immunization Monitoring Program-Active (IMPACT).

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900079-3

7 January 2021

The epidemiology of varicella–zoster virus infections: the influence of varicella on the prevalence of herpes zoster

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900079-3

7 January 2021

Immune responses of elderly persons 4 years after receiving a live attenuated varicella vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900079-3

7 January 2021

Analysis of the persistence of humoral and cellular immunity in children and adults immunized with varicella vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900079-3

7 January 2021

Varicella and herpes zoster. Changing concepts of the natural history, control, and importance of a not-so-benign virus

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900079-3

7 January 2021

Live attenuated varicella vaccine for prevention of herpes zoster

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900079-3

7 January 2021

The incidence of zoster after immunization with live attenuated varicella vaccine. A study in children with leukemia. Varicella Vaccine Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900079-3

7 January 2021

Zoster in normal children after varicella vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900079-3

7 January 2021

Live Attenuated Varicella Vaccine: Protection in Healthy Adults Compared with Leukemic Children

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900079-3

7 January 2021

10.1016/S0163-4453(03)00079-3

Identifiers

DOI

1 reference

9 August 2017

1 reference

PubMed ID

14720487